AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, has appointed Steven Caffé, as senior vice president and chief development and regulatory officer. Dr. Caffé brings 20 years of experience in global biopharmaceuticals development and regulatory approvals to AMAG. He joins AMAG from MedImmune, AstraZeneca's global biologics research and development arm, where he most recently served as senior vice president of global regulatory affairs and patient safety.

"Steve brings a wealth of relevant development and regulatory experience to AMAG, gained through a distinguished 20-year career in pharmaceutical companies ranging from Merck & Co. to MedImmune," said William Heiden, president and chief executive officer of AMAG. "His experience in global product development and life-cycle management strategies and execution will be invaluable to us near-term as we work towards the potential regulatory approval of Feraheme for the treatment of iron deficiency anaemia in a broader patient population, and longer-term as our product portfolio expands through our on-going business development activities. We are pleased to welcome Steve to AMAG."

Dr Caffé commented, "AMAG is undergoing a significant turnaround, with the continued growth of Feraheme and the addition of MuGard forming a solid foundation on which we can build a premier specialty pharmaceutical company. I am energized to join the company at this time and look forward to sharing the journey with the talented team at AMAG."